Correlates of Protection against Norovirus Infection and Disease—Where Are We Now, Where Do We Go?

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Ramani, Sasirekha ^a   Estes, Mary K ^a   Atmar, Robert L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIBODY; FUCOSYLTRANSFERASE; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NOROVIRUS; NOROVIRUS INFECTION; OUTCOME ASSESSMENT; REVIEW; VACCINATION; VIRAL GASTROENTERITIS; CALICIVIRUS INFECTION; GASTROENTERITIS; IMMUNOLOGY; VIROLOGY;

CALICIVIRIDAE INFECTIONS; GASTROENTERITIS; HUMANS; NOROVIRUS; VIRAL VACCINES;

EID: 84964728292     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005334     Document Type: Review

References (23)

1. Ramani S, Atmar RL, Estes MK, Epidemiology of human noroviruses and updates on vaccine development. Current opinion in gastroenterology. 2014;30(1):25–33. Epub 2013/11/16. doi: 10.1097/MOG.000000000000002224232370; PubMed Central PMCID: PMC3955997.
2. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY, The potential economic value of a human norovirus vaccine for the United States. Vaccine. 2012;30(49):7097–104. Epub 2012/10/03. doi: 10.1016/j.vaccine.2012.09.04023026689; PubMed Central PMCID: PMC3517973.
3. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk Virus illness. The New England journal of medicine. 2011;365(23):2178–87. Epub 2011/12/14. doi: 10.1056/NEJMoa110124522150036; PubMed Central PMCID: PMC3761795.
4. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR, Clinical immunity in acute gastroenteritis caused by Norwalk agent. The New England journal of medicine. 1977;297(2):86–9. Epub 1977/07/14. doi: 10.1056/NEJM197707142970204405590.
5. Hutson AM, Atmar RL, Graham DY, Estes MK, Norwalk virus infection and disease is associated with ABO histo-blood group type. The Journal of infectious diseases. 2002;185(9):1335–7. doi: 10.1086/33988312001052.
6. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology. 2002;122(7):1967–77. 12055602.
7. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human susceptibility and resistance to Norwalk virus infection. Nature medicine. 2003;9(5):548–53. Epub 2003/04/15. doi: 10.1038/nm86012692541.
8. Vinje J, Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol. 2015;53(2):373–81. doi: 10.1128/JCM.01535-1424989606; PubMed Central PMCID: PMC4298492.
9. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. Journal of virology. 2005;79(11):6714–22.
10. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, et al. Serological correlate of protection against norovirus-induced gastroenteritis. The Journal of infectious diseases. 2010;202(8):1212–8. Epub 2010/09/08. doi: 10.1086/65636420815703; PubMed Central PMCID: PMC2945238.
11. Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, et al. Serological Correlates of Protection against a GII.4 Norovirus. Clinical and vaccine immunology: CVI. 2015;22(8):923–9. doi: 10.1128/CVI.00196-1526041041.
12. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, et al. A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate-Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults. The Journal of infectious diseases. 2014; 210(11):1763–7. Epub 2014/06/22. doi: 10.1093/infdis/jiu33724951828.
13. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS, Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. The Journal of infectious diseases. 2011;204(12):1879–85. doi: 10.1093/infdis/jir66121998477.
14. Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, et al. Mucosal and Cellular Immune Responses to Norwalk Virus. The Journal of infectious diseases. 2015; 212(3):397–405. Epub 2015/01/31. doi: 10.1093/infdis/jiv05325635121.
15. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347(6219):269–73. doi: 10.1126/science.125810025431489; PubMed Central PMCID: PMC4398891.
16. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection. Science. 2015;347(6219):266–9. doi: 10.1126/science.125802525431490; PubMed Central PMCID: PMC4409937.
17. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science. 2014;346(6210):755–9. doi: 10.1126/science.125714725378626; PubMed Central PMCID: PMC4401463.
18. Simmons K, Gambhir M, Leon J, Lopman B, Duration of immunity to norovirus gastroenteritis. Emerging infectious diseases. 2013;19(8):1260–7. Epub 2013/07/24. doi: 10.3201/eid1908.13047223876612; PubMed Central PMCID: PMC3739512.
19. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK, Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clinical and vaccine immunology: CVI. 2015;22(2):221–8. Epub 2014/12/30. doi: 10.1128/CVI.00516-1425540269; PubMed Central PMCID: PMC4308873.
20. Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, et al. Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial. PLoS Med. 2015;12(3):e1001807.
21. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 2012;8(5):e1002705. doi: 10.1371/journal.ppat.100270522615565; PubMed Central PMCID: PMC3355092.
22. Trivedi TK, Desai R, Hall AJ, Patel M, Parashar UD, Lopman BA, Clinical characteristics of norovirus-associated deaths: a systematic literature review. American journal of infection control. 2013;41(7):654–7. Epub 2012/12/26. doi: 10.1016/j.ajic.2012.08.00223266383.
23. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK, Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clinical and vaccine immunology: CVI. 2012;19(2):284–7. Epub 2011/12/23. doi: 10.1128/CVI.05592-1122190401; PubMed Central PMCID: PMC3272916.